Literature DB >> 18173939

Update on the newer antiepileptic drugs in child neurology: advances in treatment of pediatric epilepsy.

Mazin Abdul1, James J Riviello.   

Abstract

The goal of epilepsy treatment is the prevention of recurrent seizures, and antiepileptic drugs (AEDs) are the mainstay. Uncontrolled seizures may cause medical, developmental, and psychologic disturbances. Treatment advances include 1) identification of the basic mechanisms of epilepsy and action of AEDs, 2) the introduction of many new AEDs, and 3) the use of neurostimulation, starting with vagus nerve stimulation. We must balance the efficacy of an AED versus its side effects, which if persistent, lead to patient discontinuation of the AED. Although all AEDs have a proven efficacy, they are differentiated by their efficacy for a given seizure type or epilepsy syndrome versus the side effects or tolerability. The many new AEDs give us a larger armamentarium for epilepsy treatment. We refer to studies and expert opinion consensus.

Entities:  

Year:  2007        PMID: 18173939     DOI: 10.1007/s11940-007-0041-2

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  55 in total

1.  Efficacy and safety of topiramate in refractory epilepsy of childhood: long-term follow-up study.

Authors:  Salvatore Grosso; Emilio Franzoni; Paola Iannetti; Gemma Incorpora; Cesare Cardinali; Irene Toldo; Alberto Verrotti; Filomena Caterina Moscano; Valentina Lo Faro; Luigi Mazzone; Nelia Zamponi; Clementina Boniver; Alberto Spalice; Pasquale Parisi; Guido Morgese; Paolo Balestri
Journal:  J Child Neurol       Date:  2005-11       Impact factor: 1.987

2.  The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Canadian Study Group for Childhood Epilepsy.

Authors:  H N Bawden; C S Camfield; P R Camfield; C Cunningham; H Darwish; J M Dooley; K Gordon; G Ronen; J Stewart; R van Mastrigt
Journal:  Epilepsy Res       Date:  1999-02       Impact factor: 3.045

Review 3.  Levetiracetam in pediatrics.

Authors:  Federico Vigevano
Journal:  J Child Neurol       Date:  2005-02       Impact factor: 1.987

4.  Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center.

Authors:  Howard L Kim; Jessica Aldridge; Jong M Rho
Journal:  J Child Neurol       Date:  2005-03       Impact factor: 1.987

5.  The role of tiagabine in the treatment of intractable epilepsy of childhood with multifocal independent spikes: a case report.

Authors:  C I Akman; R Schubert
Journal:  Clin Electroencephalogr       Date:  2000-10

Review 6.  Valproate as a mainstay of therapy for pediatric epilepsy.

Authors:  Renzo Guerrini
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

7.  Frontal nonconvulsive status epilepticus associated with high-dose tiagabine therapy in a child with familial bilateral perisylvian polymicrogyria.

Authors:  P Piccinelli; R Borgatti; E Perucca; A Tofani; G Donati; U Balottin
Journal:  Epilepsia       Date:  2000-11       Impact factor: 5.864

8.  Retrospective study of the use of levetiracetam in childhood seizure disorders.

Authors:  Mark W Koukkari; Edward J Guarino
Journal:  J Child Neurol       Date:  2004-12       Impact factor: 1.987

9.  Rapid infusion of sodium valproate in acutely ill children.

Authors:  Angela K Birnbaum; Robert L Kriel; Shani K Norberg; Beverly S Wical; Duy N Le; Ilo E Leppik; James C Cloyd
Journal:  Pediatr Neurol       Date:  2003-04       Impact factor: 3.372

10.  Open prospective study on oxcarbazepine in epilepsy in children: a preliminary report.

Authors:  E Franzoni; C Garone; J Sarajlija; S Gualandi; E Malaspina; I Cecconi; F C Moscano; V Marchiani
Journal:  Seizure       Date:  2006-03-22       Impact factor: 3.184

View more
  1 in total

1.  Newer anticonvulsant medications in pediatric neurology.

Authors:  Michael M Quach; Abdul Mazin; James J Riviello
Journal:  Curr Treat Options Neurol       Date:  2010-11       Impact factor: 3.598

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.